Advanced Biotherapy Inc., of Los Angeles, was issued U.S. Patent No. 6,534,059 for the use of antibody to gamma interferon to treat corneal transplant rejection, a patent the company said would not expire until June 2021.

Aethlon Medical Inc., of La Jolla, Calif., said the U.S. Patent and Trademark Office approved and issued U.S. Patent No. 6,528,057 titled "Method for removal of HIV and other viruses from blood." The patent, exclusively licensed to Aethlon from an undisclosed partner, addresses a method to remove viruses and protein toxins in patients suffering from HIV and other chronic viral illnesses such as hepatitis C.

Amnis Corp., of Seattle, was issued U.S. Patent Nos. 6,507,391 and 6,532,061, which could play a role in helping it create a next-generation cell analysis platform. The patents cover techniques to measure the velocity of cells in flow over a range of cell concentrations and flow rates.

AusAm Biotechnologies Inc., of Santa Monica, Calif., received a second U.S. patent covering methods for detecting kidney disease. Specifically, the patent covers methods for detecting intact modified albumin in urine through analysis by chromatography, electrophoresis, sedimentation or antibodies.

Chiron Corp., of Emeryville, Calif., was granted U.S. Patent No. 6,531,276, which is directed to nucleic acid testing methods for HIV-1. In addition to its application in screening blood donations, Chiron said the technology plays an important role in the treatment of HIV-positive patients.

CV Therapeutics Inc., of Palo Alto, Calif., received a notice of allowance and two newly issued U.S. patents granting additional issued claims related to its lead compound, Ranexa (ranolazine). CV said the new patents broaden coverage for sustained-release ranolazine formulations for the potential treatment of chronic angina beyond the claims obtained two years ago.

Genzyme Molecular Oncology, a unit of Genzyme Corp., of Cambridge, Mass., was issued U.S. Patent No. 6,528,060 covering a peptide with potential applications for breast and ovarian cancers. Genzyme said the discovery was made using its SPHERE (solid phase epitope recovery) screening technology.

Interleukin Genetics Inc., of Waltham, Mass., was awarded U.S. Patent No. 6,524,795 for the discovery that certain common variations in interleukin-1 (IL-1) genes are associated with an increased risk for heart disease. The company said studies have demonstrated that one pattern of IL-1 SNPs leads to an increased risk of acute myocardial infarction, and a second pattern is associated with an increased risk of clogged heart arteries that produce angina.

Novacea Inc., of South San Francisco, said the Oregon Health & Science University in Portland was issued U.S. Patent No. 6,521,608 titled "Vitamin D and its analogues in the treatment of tumors and other hyperproliferative disorders." Privately held Novacea is using the technology supporting the patent to develop a cancer treatment called DN-101, a pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin D.

Sangamo BioSciences Inc., of Richmond, Calif., was granted a U.S. patent titled "Regulation of Endogenous Gene Expression in Cells Using Zinc Finger Proteins." The patent includes claims covering the activation or repression of any endogenous gene in any cell type using zinc finger DNA-binding proteins.

Senesco Technologies Inc., of New Brunswick, N.J., was awarded U.S. Patent No. 6,538,182 titled "DNA Encoding A Plant Deoxyhypusine Synthase, a Plant Eukaryotic Initiation Factor 5A, Transgenic Plants and a Method for Controlling Senescence Programmed Cell Death in Plants." Senesco said it has used the deoxyhypusine synthase and eukaryotic initiation Factor 5A genes to delay natural and stress-induced plant cell death, yielding beneficial traits in a variety of agricultural products.